Scarica l'app Stockscreener
883.96
3.67%
-33.69
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$917.65
Aprire:
$900.01
Volume 24 ore:
4.45M
Relative Volume:
1.43
Capitalizzazione di mercato:
$789.69B
Reddito:
$65.18B
Utile/perdita netta:
$20.64B
Rapporto P/E:
39.13
EPS:
22.5894
Flusso di cassa netto:
$5.96B
1 W Prestazione:
-4.65%
1M Prestazione:
-2.11%
6M Prestazione:
+7.09%
1 anno Prestazione:
+2.82%
Intervallo 1D:
$871.73
$900.42
Intervallo di 1 settimana:
$871.73
$930.00
Portata 52W:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
883.96 | 789.69B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.50 | 547.64B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
198.71 | 351.47B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
189.75 | 294.27B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
145.47 | 277.58B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Downgrade | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Street - The Motley Fool
Is Eli Lilly Stock Worth Watching Right Now - Kalkine Media
KLP Kapitalforvaltning AS Has $331.30 Million Position in Eli Lilly and Company $LLY - MarketBeat
Branded Pharma Q4 Earnings Review: Merck and Eli Lilly Performance Analysis 2026News and Statistics - IndexBox
Eli Lilly and Company $LLY Shares Purchased by Caprock Group LLC - MarketBeat
Fishman Jay A Ltd. MI Buys 1,344 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Weight Loss Pill Records Modest Second Week Sales - HarianBasis.co
Should You Add a Healthcare Stock to Your Portfolio This Month? And Should It Be Eli Lilly (LLY)? - The Motley Fool
Why Eli Lilly (LLY) Shares Are Trading Lower Today - Yahoo Finance UK
Ticino Wealth Makes New $1.31 Million Investment in Eli Lilly and Company $LLY - MarketBeat
Optas LLC Has $4.18 Million Position in Eli Lilly and Company $LLY - MarketBeat
PFG Advisors Sells 3,261 Shares of Eli Lilly and Company $LLY - MarketBeat
$Eli Lilly and Co (LLY.US)$ Monday 917 and will keep up for few more days. - Moomoo
Why Eli Lilly Stock Flopped on Friday - Yahoo Finance
Eli Lilly and Company (NYSE:LLY) Trading Down 3.6%Time to Sell? - MarketBeat
Eli Lilly and Co (LLY) Stock Price, Trades & News - GuruFocus
Eli Lilly and Co (LLY) Stock Down 3.7% -- Now Undervalued? GF Sc - GuruFocus
Foundayo's Prescription Performance Raises Concerns for Eli Lill - GuruFocus
Stock Quote & Chart | Eli Lilly and Company - investor.lilly.com
A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B - statnews.com
Lilly's obesity pill records modest second week as battle with Novo intensifies - Reuters
Eli Lilly shares see Morgan Stanley commentary on Mounjaro, Zepbound scripts - Investing.com Canada
Lilly’s CAR-T devotion; CBER’s next top dog? - Pharma Voice
Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow - TechStock²
LLY Stock Slides Toward Sixth Weekly Loss, But 200-DMA Holds Firm: Is It Setting Up For Earnings Run? - Stocktwits
Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims - Yahoo Finance
Eli Lilly slides as weekly GLP-1 prescription data raises near-term demand questions - Quiver Quantitative
Eli Lilly and Co Stock (LLY) Moved Down by 3.03% on Apr 24: What Investors Need To Know - TradingKey
Eli Lilly Shares Dip Despite Stable Growth in GLP-1 Prescriptions - Yahoo Finance
Eli Lilly (LLY) Faces Pressure as Weight Loss Drug Prescriptions Lag Behind Competitor - GuruFocus
Lilly’s New Obesity Pill Off to Slow Start in Race With Novo - Bloomberg
LLY stock clings to 200-DMA as sell-off deepens: Retail eyes 'positioning' play ahead of Q1 earnings next week - MSN
Eli Lilly slips as obesity scripts said to trail those for Novo’s Wegovy - Seeking Alpha
Eli Lilly stock slips despite steady GLP-1 script growth By Investing.com - Investing.com UK
Eli Lilly stock slips despite steady GLP-1 script growth - Investing.com
Ahead of Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? - Morningstar
Eli Lilly and Company $LLY Shares Sold by Silphium Asset Management Ltd - MarketBeat
Drug company Lilly refuses to list Mounjaro on PBS, says price too low - AFR
LLY Stock Price, Quote & Chart | ELI LILLY & CO (NYSE:LLY) - ChartMill
Eli Lilly (LLY) Expands Partnership with Hims & Hers - TipRanks
List of 33 Acquisitions by Lilly (Apr 2026) - Tracxn
Eli Lilly (LLY) Expands Weight-Loss Offerings Through Hims & Hers Partnership - GuruFocus
Eli Lilly & Co. is opening a Lilly Gateway Labs biotech incubator in Philadelphia - MSN
BofA raises Hims and Hers stock price target on Lilly partnership - Investing.com
Hims & Hers jumps 7% after expanding partnership with Eli Lilly - Yahoo Finance
Hims & Hers Adds Lilly GLP-1 Treatments To Lineup – CEO Compares It To Netflix’s Early Days - Stocktwits
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q1 Earnings - TradingView
Hims & Hers stock surges 7% on Eli Lilly partnership expansion - Investing.com
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Community Health (CYH) - The Globe and Mail
AI Models Split on Eli Lilly (LLY) as Growth Strengths Collide With Valuation Risks - TipRanks
Lilly Q1 2026 earnings conference call - Moomoo
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lilly Eli Co Azioni (LLY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Montarce Lucas | EVP & CFO |
Feb 16 '26 |
Option Exercise |
0.00 |
368 |
0 |
16,418 |
| Custer Kenneth L. | EVP & President, Card Met Hlth |
Feb 16 '26 |
Option Exercise |
0.00 |
207 |
0 |
10,232 |
| Brown Adrienne S | EVP, President LLY Imm |
Feb 16 '26 |
Option Exercise |
0.00 |
391 |
0 |
5,312 |
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab |
Feb 01 '26 |
Option Exercise |
0.00 |
3,394 |
0 |
29,654 |
| Skovronsky Daniel | EVP, CS&PO & Pres. LRL |
Feb 01 '26 |
Option Exercise |
0.00 |
12,684 |
0 |
150,165 |
| Van Naarden Jacob | EVP,Pres LLY Oncology&HdCorpBD |
Feb 01 '26 |
Option Exercise |
0.00 |
4,108 |
0 |
24,670 |
| Ricks David A | President, Chair, and CEO |
Feb 01 '26 |
Option Exercise |
0.00 |
31,932 |
0 |
547,098 |
| Rau Diogo | EVP & CIDO |
Feb 01 '26 |
Option Exercise |
0.00 |
3,752 |
0 |
23,471 |
| Jonsson Patrik | EVP & President, LLY Int'l |
Feb 01 '26 |
Option Exercise |
0.00 |
3,930 |
0 |
57,581 |
| Hernandez Edgardo | EVP & Pres., Mfg. Operations |
Feb 01 '26 |
Option Exercise |
0.00 |
3,572 |
0 |
43,303 |
1.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):